Abbott Laboratories
ABT
$123.62
-$1.05-0.84%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.12% | 36.64% | 8.16% | 478.98% | 14.62% |
| Total Depreciation and Amortization | -1.25% | -3.48% | -6.09% | -0.74% | -2.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.56% | 0.71% | -4.93% | 147.08% | 0.00% |
| Change in Net Operating Assets | 64.54% | -126.04% | 27.20% | -2,084.91% | 128.20% |
| Cash from Operations | 3.03% | 4.44% | 38.24% | -5.60% | 44.11% |
| Capital Expenditure | 10.79% | 5.82% | -21.61% | 4.64% | 0.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 347.37% | -163.29% | 151.85% | -111.59% | -65.22% |
| Cash from Investing | 23.06% | -28.48% | -10.59% | -5.10% | 6.31% |
| Total Debt Issued | -100.00% | -99.10% | -- | -95.45% | -- |
| Total Debt Repaid | -1,273.81% | 72.13% | -716.54% | 36.11% | 102.79% |
| Issuance of Common Stock | -25.00% | 169.23% | 114.18% | -26.47% | 64.29% |
| Repurchase of Common Stock | 59.39% | -100.00% | -23.89% | -21.62% | -37,450.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.40% | -7.08% | -7.21% | -7.88% | -8.11% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -11.68% | -38.69% | -74.74% | 9.31% | 32.65% |
| Foreign Exchange rate Adjustments | -127.78% | 492.31% | 166.67% | -432.00% | 224.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.93% | -40.40% | -77.12% | -68.98% | 150.71% |